Capstone Investment Advisors
PTGX icon

Capstone Investment Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Capstone Investment Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,676
Closed -$510K – 1961
2025
Q3 		$510K Buy
7,676
+689
+10% +$39.2K ﹤0.01% 1361
2025
Q2 		$386K Buy
+6,987
New +$335K ﹤0.01% 1266

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capstone Investment Advisors's PTGX Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 7,676 shares — an estimated $510K sold.

Capstone Investment Advisors first reported a position in PTGX in Q2 2025 and held it in 2 quarters. The position peaked at $510K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 7,676 Protagonist Therapeutics shares in Q4 2025, an estimated $510K.
  • Capstone Investment Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 2 quarters.
  • Capstone Investment Advisors's Protagonist Therapeutics position peaked at $510K in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.